Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Authors
Cunningham, DChau, I
Stocken, D
Valle, Juan W
Smith, David
Steward, William P
Harper, P
Dunn, J
Tudur-Smith, C
West, J
Falk, S
Crellin, A
Adab, Fawzi
Thompson, J
Leonard, P
Ostrowski, J
Eatock, M
Scheithauer, W
Herrmann, R
Neoptolemos, J
Affiliation
Royal Marsden National HealthService (NHS) Foundation Trust, London and Surrey, United Kingdom. david.cunningham@rmh.nhs.ukIssue Date
2009-11-20
Metadata
Show full item recordAbstract
PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP). PATIENTS AND METHODS: Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance statusCitation
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. 2009, 27 (33):5513-8 J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2009.24.2446PubMed ID
19858379Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2009.24.2446